Zelira Therapeutics Limited

ASX:ZLD Stok Raporu

Piyasa değeri: AU$8.1m

Zelira Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Zelira Therapeutics's earnings have been declining at an average annual rate of -41.7%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 3.5% per year.

Anahtar bilgiler

-41.7%

Kazanç büyüme oranı

-20.6%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi31.2%
Gelir büyüme oranı-3.5%
Özkaynak getirisin/a
Net Marj-38,513.0%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Jul 14
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Jan 19
Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Sep 25
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Jun 03
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Dec 31
A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Gelir ve Gider Dağılımı

Zelira Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

ASX:ZLD Gelir, gider ve kazançlar (AUD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-3723
31 Mar 240-3632
31 Dec 230-3641
30 Sep 230-2141
30 Jun 230-651
31 Mar 231-882
31 Dec 221-10102
30 Sep 221-11112
30 Jun 222-12121
31 Mar 221-11101
31 Dec 211-1081
30 Sep 211-982
30 Jun 211-972
31 Mar 210-863
31 Dec 200-854
30 Sep 200-854
30 Jun 200-744
31 Mar 200-633
31 Dec 191-433
30 Sep 191-423
30 Jun 191-422
31 Mar 191-312
31 Dec 180-312
30 Sep 180-312
30 Jun 180-212
31 Mar 180-212
31 Dec 170-211
30 Sep 170-411
30 Jun 170-621
31 Dec 160-520
30 Jun 160000

Kaliteli Kazançlar: ZLD is currently unprofitable.

Büyüyen Kar Marjı: ZLD is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.

Büyüme Hızlandırma: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


Özkaynak Getirisi

Yüksek ROE: ZLD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin